COMMUNIQUÉS West-GlobeNewswire

Solon Eiendom ASA - Primary insider notification

12/06/2017 - 17:14

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 12 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company [...]

Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies

12/06/2017 - 17:01

Novel mRNA-based antibody drug class holds promise for fast development of potent immunotherapies MAINZ, Germany, June 12, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering [...]

Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer

12/06/2017 - 15:00

DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein [...]

ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

12/06/2017 - 15:00

SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77 th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to support once-monthly [...]

Solon Eiendom ASA : Bionor Pharma winding down operations

12/06/2017 - 12:52

Oslo, June 12, 2017 As previously communicated, the biopharmaceutical division engaged a team of international industry experts to propose an updated development plan and strategic partnership assessment. The team has [...]

Saniona AB: Saniona publishes prospectus for listing of shares on Nasdaq Stockholm

12/06/2017 - 12:15

PRESS RELEASE 12 June 2017 Saniona AB (publ) ("Saniona" or the "Company") has prepared a prospectus for admission to trading of the Company's shares at Nasdaq Stockholm. Last day of trading at Nasdaq First North Premier [...]

DBV Technologies : Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social

12/06/2017 - 11:19

Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Place de cotation : NYSE Euronext [...]

DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company

12/06/2017 - 11:19

Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

12/06/2017 - 09:00

FIT Biotech Oy Company release June 12, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Zealand to regain control of elsiglutide

12/06/2017 - 08:48

Zealand to regain control of elsiglutide Helsinn returns elsiglutide to Zealand Zealand now has full rights to develop products within cancer-supportive care Lugano, Switzerland and Copenhagen, Denmark, June 12, 2017 - [...]

Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan

12/06/2017 - 08:00

Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan Herantis Pharma Plc Company release 12 June 2017 at 9:00 am Finnish Medicines Agency Fimea has [...]

Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX®

12/06/2017 - 08:00

Press Release 12 June 2017 Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX® --New Designation is One of the First Cell-based Therapy Names Established by the [...]

Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma

12/06/2017 - 07:15

The Adult Brain Tumor Consortium (ABTC) is designed to develop more effective treatments for malignant brain tumors. It is funded by the US National Cancer Institute (NCI). The ABTC will conduct a clinical phase 1 study [...]

TiGenix announces final equity payment for cardiac platform acquisition

12/06/2017 - 07:00

PRESS R ELEASE regulated information Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory [...]

TiGenix annonce le paiement final en actions pour l'acquisition de sa plateforme cardiaque

12/06/2017 - 07:00

Communiqué de Presse Information réglementée Louvain (BELGIQUE) - 12 juin 2017, 7:00 h CEST - TiGenix NV (Euronext Brussels et NASDAQ: TIG), une société biopharmaceutique de pointe spécialisée dans l'exploration de [...]

Probiodrug announces encouraging results of the Phase 2a SAPHIR Study

11/06/2017 - 21:06

Probiodrug announces encouraging results of the Phase 2a SAPHIR Study HALLE (SAALE), Germany, 11 June 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to [...]

Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

11/06/2017 - 17:01

Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent ® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia - Data presented at the 77 th Scientific Sessions of [...]

Sanofi et Regeneron annoncent les résultats positifs des premières études consacrées à l'évaluation de Praluent® (alirocumab) chez des personnes présentant un diabète et une hypercholestérolémie

11/06/2017 - 17:01

Sanofi et Regeneron annoncent les résultats positifs des premières études consacrées à l'évaluation de Praluent ® (alirocumab) chez des personnes présentant un diabète et une hypercholestérolémie - Les données de ces [...]

New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%

10/06/2017 - 19:14

Pressrelease - No. 6/2017 New analysis shows Soliqua ® 100/33 lowered HbA 1c by more than 2% in patients with screening levels greater than 9% All subgroups treated with Soliqua ® 100/33 achieved a mean HbA 1c of less [...]